New Blood Test May Revolutionize Cancer Diagnosis, Study Finds
A groundbreaking blood test has been shown to detect more than 50 types of cancer at an early stage, potentially leading to improved treatment outcomes. The test, known as Galleri, can identify fragments of cancerous DNA that have broken off a tumor and are circulating in the bloodstream.
The study, which involved 25,000 adults from the US and Canada over a year, found that nearly one in 100 participants received a positive result, with 62% of those cases confirmed as cancer. The test was able to detect cancer at an early stage in more than half of cases, where treatment is often most effective.
Lead researcher Dr. Nima Nabavizadeh noted that the test could "fundamentally change" their approach to cancer screening, allowing for earlier detection and potentially curative treatments. When combined with existing screening programs for breast, bowel, lung, and cervical cancers, the Galleri test increased the number of cancers detected sevenfold.
However, scientists caution that further research is needed to confirm the test's effectiveness in reducing deaths from cancer. Clare Turnbull, a professor of translational cancer genetics at The Institute of Cancer Research, London, emphasized the need for larger studies with mortality as an endpoint to establish whether the Galleri test translates into benefits in mortality.
The NHS has already expressed interest in extending the test to a further one million people if it proves successful. The results of a three-year trial involving 140,000 NHS patients in England will be published next year.
While the findings are promising, experts stress that overdiagnosis must also be considered. "Avoiding overdiagnosing cancers that may not have caused harm" is crucial when introducing new screening tests, warns Naser Turabi of Cancer Research UK.
The Galleri test has sparked excitement among scientists and healthcare professionals, with some hailing it as a major breakthrough in cancer diagnosis. As the trial results continue to unfold, one thing is clear: this innovative blood test may revolutionize cancer diagnosis and treatment.
A groundbreaking blood test has been shown to detect more than 50 types of cancer at an early stage, potentially leading to improved treatment outcomes. The test, known as Galleri, can identify fragments of cancerous DNA that have broken off a tumor and are circulating in the bloodstream.
The study, which involved 25,000 adults from the US and Canada over a year, found that nearly one in 100 participants received a positive result, with 62% of those cases confirmed as cancer. The test was able to detect cancer at an early stage in more than half of cases, where treatment is often most effective.
Lead researcher Dr. Nima Nabavizadeh noted that the test could "fundamentally change" their approach to cancer screening, allowing for earlier detection and potentially curative treatments. When combined with existing screening programs for breast, bowel, lung, and cervical cancers, the Galleri test increased the number of cancers detected sevenfold.
However, scientists caution that further research is needed to confirm the test's effectiveness in reducing deaths from cancer. Clare Turnbull, a professor of translational cancer genetics at The Institute of Cancer Research, London, emphasized the need for larger studies with mortality as an endpoint to establish whether the Galleri test translates into benefits in mortality.
The NHS has already expressed interest in extending the test to a further one million people if it proves successful. The results of a three-year trial involving 140,000 NHS patients in England will be published next year.
While the findings are promising, experts stress that overdiagnosis must also be considered. "Avoiding overdiagnosing cancers that may not have caused harm" is crucial when introducing new screening tests, warns Naser Turabi of Cancer Research UK.
The Galleri test has sparked excitement among scientists and healthcare professionals, with some hailing it as a major breakthrough in cancer diagnosis. As the trial results continue to unfold, one thing is clear: this innovative blood test may revolutionize cancer diagnosis and treatment.